The efficacy of azapirones is uncertain due to the lack of meta-analysable data for the primary outcome and low- quality evidence for secondary efficacy outcomes .
A small amount of moderate- quality evidence suggested that the acceptability of azapirones for panic disorder was lower than for placebo .
If further research is to be conducted , studies with larger sample sizes , with different azapirones and with less risk of bias are necessary to draw firm conclusions regarding azapirones for panic disorder
BACKGROUND Panic disorder is common in the general population .
It is often associated with other psychiatric disorders , such as drug dependence , major depression , bipolar disorder , social phobia , specific phobia and generalised anxiety disorder .
Azapirones are a class of drugs used as anxiolytics .
They are associated with less drowsiness , psychomotor impairment , alcohol potentiation and potential for addiction or abuse than benzodiazepines .
However , azapirones are not widely used in the treatment of panic disorder and evidence for their efficacy is unclear .
It is important to find out if azapirones are effective and acceptable in the treatment of panic disorder .
OBJECTIVES To assess the effects of azapirones on panic disorder in adults , specifically:1 .
to determine the efficacy of azapirones in alleviating symptoms of panic disorder , with or without agoraphobia , in comparison with placebo;2 .
to review the acceptability of azapirones in panic disorder , with or without agoraphobia , in comparison with placebo ; and 3 .
to investigate adverse effects of azapirones in panic disorder with or without agoraphobia , including general prevalence of adverse effects , compared with placebo .
Buspirone Therapy in Anxious Elderly Patients: A Controlled Clinical Trial
& NA ; Forty patients over 65 years of age with anxiety symptoms due to an anxiety state ( N = 20 ) or secondary to neurotic depression ( N = 20 ) took part in a double‐blind , placebo‐controlled trial conducted in a primary care practice . All patients were receiving concomitant drug therapy for chronic medical conditions ; 70 % were receiving two or more nonpsychotropic drugs in addition to the study medication . Patients were r and omly assigned to treatment with buspirone 5‐30 mg/day or placebo for 4 weeks , with clinical evaluations made weekly . One buspironetreated and two placebo‐treated patients discontinued treatment after 2 weeks because of lack of efficacy  . Buspirone treatment result ed in significantly greater ( p ≤ 0.05 ) improvement on the Hamilton Rating Scale for Anxiety , Hamilton Rating Scale for Depression , and Clinical Global Impression assessment than did placebo  . Mild adverse experiences were reported by five buspirone‐treated and nine placebotreated patients . Buspirone ( mean dose , 18 mg/day ) proved equally effective for elderly patients suffering anxiety states or neurotic depression at doses similar to those used in younger patients , and was well tolerated by elderly patients receiving treatment for other chronic medical conditions
The efficacy of azapirones is uncertain due to the lack of meta-analysable data for the primary outcome and low- quality evidence for secondary efficacy outcomes .
A small amount of moderate- quality evidence suggested that the acceptability of azapirones for panic disorder was lower than for placebo .
If further research is to be conducted , studies with larger sample sizes , with different azapirones and with less risk of bias are necessary to draw firm conclusions regarding azapirones for panic disorder
BACKGROUND Panic disorder is common in the general population .
It is often associated with other psychiatric disorders , such as drug dependence , major depression , bipolar disorder , social phobia , specific phobia and generalised anxiety disorder .
Azapirones are a class of drugs used as anxiolytics .
They are associated with less drowsiness , psychomotor impairment , alcohol potentiation and potential for addiction or abuse than benzodiazepines .
However , azapirones are not widely used in the treatment of panic disorder and evidence for their efficacy is unclear .
It is important to find out if azapirones are effective and acceptable in the treatment of panic disorder .
OBJECTIVES To assess the effects of azapirones on panic disorder in adults , specifically:1 .
to determine the efficacy of azapirones in alleviating symptoms of panic disorder , with or without agoraphobia , in comparison with placebo;2 .
to review the acceptability of azapirones in panic disorder , with or without agoraphobia , in comparison with placebo ; and 3 .
to investigate adverse effects of azapirones in panic disorder with or without agoraphobia , including general prevalence of adverse effects , compared with placebo .